DNA RNA and Cells

21 Aug 2017 Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse
18 Aug 2017 Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer
18 Aug 2017 Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center
17 Aug 2017 SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's pexastimogene devacirepvec (Pexa-Vec) Oncolytic Immunotherapy
17 Aug 2017 Kite Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3
15 Aug 2017 Publication in EMBO Molecular Medicine Demonstrates CureVac's Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors
15 Aug 2017 Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration
12 Aug 2017 Ionis to Independently Advance Inotersen and IONIS-FB-L Rx
10 Aug 2017 CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial
10 Aug 2017 REGENXBIO Announces IND Active for Phase I Trial of RGX-111 to Treat Mucopolysaccharidosis Type I
08 Aug 2017 RXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing
08 Aug 2017 Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
07 Aug 2017 Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection
07 Aug 2017 Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
05 Aug 2017 MiMedx Files With The FDA To Initiate Its Investigational New Drug Achilles Tendonitis Phase 3 Clinical Trial
03 Aug 2017 VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers
03 Aug 2017 BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies
03 Aug 2017 MiMedx Reports Exceptional Results in Phase 2B Clinical Trial on the Use of AmnioFix® Injectable in the Treatment of Plantar Fasciitis
02 Aug 2017 Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
02 Aug 2017 Orbsen Therapeutics Receives Approval from European Regulators for Clinical Trial of Breakthrough Cell Therapy for Diabetic Kidney Disease
02 Aug 2017 Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA™ (voretigene neparvovec)
01 Aug 2017 uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
01 Aug 2017 Homology Medicines Announces $83.5 Million Series B Financing to Advance Lead Development Candidate and AMEnDR™ In Vivo Gene Editing Technology
01 Aug 2017 NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
01 Aug 2017 Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing